Skip to main content
SpringerLink
Log in

Cystic Fibrosis-related Diabetes

  • Chapter
  • First Online:
Diabetes Management in Hospitalized Patients

Part of the book series: Contemporary Endocrinology ((COE))

  • 269 Accesses

Abstract

Cystic fibrosis (CF) is a genetic disorder that is primarily known to impact the lungs; however, many patients are also diagnosed with diabetes referred to as CF-related diabetes (CFRD), an entity with overlapping features of Type 1 and Type 2 diabetes. Outpatient annual screening is recommended in CF Centers to aid in early diagnosis and management; however, challenges arise during CF pulmonary exacerbations requiring hospitalization. Thus, clinicians may encounter CFRD in the setting of acute illness in people with CF, highlighting the importance of understanding this CF complexity. In this chapter, we review the pathophysiology, diagnosis, management strategies, and outcomes of CFRD, with an additional focus on inpatient diagnosis and management of CFRD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Anderson D. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56(2):344–99.

    Article  Google Scholar 

  2. Cystic Fibrosis Foundation Patient Registry 2020 Annual Data Report Bethesda, Maryland ©2021 Cystic Fibrosis Foundation.

    Google Scholar 

  3. Cystic fibrosis-related diabetes clinical care guidelines [Internet]. Cystic Fibrosis Foundation. [cited 2022 Oct 17]. https://www.cff.org/medical-professionals/cystic-fibrosis-related-diabetes-clinical-care-guidelines#clinical-care-guidelines-for-cystic-fibrosis-related-diabetes-executive-summary

  4. Ballmann M. Cystic fibrosis-related diabetes (CFRD). Cystic fibrosis—facts, management and advances; 2021.

    Google Scholar 

  5. Kayani K, Mohammed R, Mohiaddin H. Cystic fibrosis-related diabetes. Front Endocrinol (Lausanne). 2018;9:20. https://doi.org/10.3389/fendo.2018.00020. Cystic Fibrosis Foundation.

    Article  PubMed  Google Scholar 

  6. Yang SN, Berggren PO. Beta-cell CaV channel regulation in physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2005;288(1):E16–28. https://doi.org/10.1152/ajpendo.00042.2004.

    Article  CAS  PubMed  Google Scholar 

  7. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. Physiol Rev. 1999;79(1 Suppl):S145–66. https://doi.org/10.1152/physrev.1999.79.1.S145.

    Article  CAS  PubMed  Google Scholar 

  8. Moheet A, Moran A. CF-related diabetes: containing the metabolic miscreant of cystic fibrosis. Pediatr Pulmonol. 2017;52(S48):S37–43. https://doi.org/10.1002/ppul.23762. Epub 2017 Jul 17

    Article  PubMed  Google Scholar 

  9. Lanng S, Thorsteinsson B, Røder ME, Orskov C, Holst JJ, Nerup J, Koch C. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance. Acta Endocrinol. 1993;128(3):207–14. https://doi.org/10.1530/acta.0.1280207.

    Article  CAS  Google Scholar 

  10. Ewald N, Hardt PD. Diagnosis and treatment of diabetes mellitus in chronic pancreatitis. World J Gastroenterol. 2013;19(42):7276–81. https://doi.org/10.3748/wjg.v19.i42.7276.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Edlund A, Pedersen M, Lindqvist A, et al. CFTR is involved in the regulation of glucagon secretion in human and rodent alpha cells. Sci Rep. 2017;7:90. https://doi.org/10.1038/s41598-017-00098-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Jing X, Li DQ, Olofsson CS, Salehi A, Surve VV, Caballero J, Ivarsson R, Lundquist I, Pereverzev A, Schneider T, Rorsman P, Renström E. CaV2.3 calcium channels control second-phase insulin release. J Clin Invest. 2005 Jan;115(1):146–54. https://doi.org/10.1172/JCI22518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kuo P, Stevens JE, Russo A, Maddox A, Wishart JM, Jones KL, et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis – effects of pancreatic enzyme supplementation. J Clin Endocrinol Metab. 2011;96(5):851–5. https://doi.org/10.1210/jc.2010-2460.

    Article  CAS  Google Scholar 

  14. Merjaneh L, Toprak D, McNamara S, Nay L, Sullivan E, Rosenfeld M. Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinol Diabetes Metab. 2020;4(2):e00208.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626–31. https://doi.org/10.2337/dc09-0586. Epub 2009 Jun 19.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000;162(3 Pt 1):891–5. https://doi.org/10.1164/ajrccm.162.3.9904075.

    Article  CAS  PubMed  Google Scholar 

  17. Prentice BJ, Jaffe A, Hameed S, Verge CF, Waters S, Widger J. Cystic fibrosis-related diabetes and lung disease: an update. Eur Respir Rev. 2021;30(159):200293.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Kaminski BA, Goldsweig BK, Sidhaye A, Blackman SM, Schindler T, Moran A. Cystic fibrosis related diabetes: nutrition and growth considerations. J Cyst Fibros. 2019;18:S32–7.

    Article  CAS  PubMed  Google Scholar 

  19. Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: what can be done? Diabetes Obes Metab. 2017;19(12):1655–68. https://doi.org/10.1111/dom.13009. Epub 2017 Jul 13.

    Article  PubMed  Google Scholar 

  20. Konrad K, Thon A, Fritsch M, Fröhlich-Reiterer E, Lilienthal E, Wudy SA, Holl RW, German/Austrian Diabetes Prospective Documentation Initiative. Comparison of cystic fibrosis-related diabetes with type 1 diabetes based on a German/Austrian Pediatric Diabetes Registry. Diabetes Care. 2013;36(4):879–86. https://doi.org/10.2337/dc12-0807. Epub 2012 Dec 13.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL. Cystic fibrosis related diabetes: medical management. J Cyst Fibros. 2019;18:S10. https://doi.org/10.1016/j.jcf.2019.08.003.

    Article  CAS  PubMed  Google Scholar 

  22. Lewis C, Blackman SM, Nelson A, Oberdorfer E, Wells D, Dunitz J, Thomas W, Moran A. Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med. 2015;191(2):194–200. https://doi.org/10.1164/rccm.201403-0576oc.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pencharz PB, Durie PR. Nutritional management of cystic fibrosis. Annu Rev Nutr. 1993;13:111–36.

    Article  CAS  PubMed  Google Scholar 

  24. Beaudoin N, Bouvet G, Coriati A, Rabasa-Lhoret R, Berthiaume Y. Combined exercise training improves glycemic control in adult with cystic fibrosis. Med Sci Sports Exerc. 2017;49(2):231–7. https://doi.org/10.1249/mss.0000000000001104.

    Article  PubMed  Google Scholar 

  25. Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, Taylor-Cousar J, Wang C, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012;6(5):1038–44. https://doi.org/10.1177/193229681200600507.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Ode KL, Ballman M, Battezzati A, Brennan A, Chan CL, Hameed S, Ismail HM, Kelly A, Moran AM, Rabasa-Lhoret R, Saxby NA, Craig ME. ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2022;23(8):1212–28. https://doi.org/10.1111/pedi.13453.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2016;4:CD004730. https://doi.org/10.1002/14651858.cd004730.pub4.

    Article  PubMed  Google Scholar 

  28. Grover P, Thomas W, Moran A. Glargine versus NPH insulin in cystic fibrosis related diabetes. J Cyst Fibros. 2008;7(2):134–6. https://doi.org/10.1016/j.jcf.2007.07.004.

    Article  CAS  PubMed  Google Scholar 

  29. Scheuing N, Thon A, Konrad K, Bauer M, Karsten C, Meissner T, Seufert J, Schönau E, Schöfl C, Woelfle J, Holl RW. Carbohydrate intake and insulin requirement in children, adolescents and young adults with cystic fibrosis-related diabetes: a multicenter comparison to type 1 diabetes. Clin Nutr. 2015;34(4):732–8. https://doi.org/10.1016/j.clnu.2014.08.016.

    Article  CAS  PubMed  Google Scholar 

  30. Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M. Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis. J Cyst Fibros. 2022;22:39. https://doi.org/10.1016/j.jcf.2022.07.013.

    Article  CAS  PubMed  Google Scholar 

  31. Scully KJ, Marchetti P, Sawicki GS, Uluer A, Cernadas M, Cagnina RE, Kennedy JC, Putman MS. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):258–63. https://doi.org/10.1016/j.jcf.2021.09.001.

    Article  CAS  PubMed  Google Scholar 

  32. Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ. Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros. 2018;17(6):798–803. https://doi.org/10.1016/j.jcf.2018.05.005.

    Article  CAS  PubMed  Google Scholar 

  33. Agrawal A, Agarwal A, Mehta D, Sikachi RR, Du D, Wang J. Nationwide trends of hospitalizations for cystic fibrosis in the United States from 2003 to 2013. Intractable Rare Dis Res. 2017;6(3):191–8.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Okoniewski W, Hughan KS, Weiner GA, Weiner DJ, Forno E. Glycemic control and FEV1 recovery during pulmonary exacerbations in pediatric cystic fibrosis-related diabetes. J Cyst Fibros. 2020;19(3):460–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report Bethesda, Maryland ©2022 Cystic Fibrosis Foundation.

    Google Scholar 

  36. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Leon J, Lyons SK, Perry ML, Prahalad P, Pratley RE, Seley JJ, Stanton RC, Gabbay RA. 16. Diabetes care in the hospital: standards of care in diabetes—2023. Diabetes Care. 2022;46(Supplement_1):S267. https://doi.org/10.2337/dc23-s016.

    Article  PubMed Central  Google Scholar 

  37. Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a diabetes mellitus comprehensive care plan—2022 update. Endocr Pract. 2022;28(10):923–1049. https://doi.org/10.1016/j.eprac.2022.08.002.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Onady GM, Stolfi A. Drug treatments for managing cystic fibrosis-related diabetes. Cochrane Database Syst Rev. 2020;2020(10):CD004730. https://doi.org/10.1002/14651858.cd004730.pub5.

    Article  PubMed Central  Google Scholar 

  39. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B. Clinical care guidelines for cystic fibrosis–related diabetes. Diabetes Care. 2010;33(12):2697–708. https://doi.org/10.2337/dc10-1768.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL. Ispad clinical practice consensus guidelines 2018: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes. 2018;19:64–74. https://doi.org/10.1111/pedi.12732.

    Article  PubMed  Google Scholar 

  41. Prandin; 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020741s038lbl.pdf

  42. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin Lispro or repaglinide in cystic fibrosis–related diabetes. Diabetes Care. 2001;24(10):1706–10. https://doi.org/10.2337/diacare.24.10.1706.

    Article  CAS  PubMed  Google Scholar 

  43. Nyirjesy SC, Peleckis AJ, Eiel JN, Gallagher K, Doliba A, Tami A, Flatt AJ, De Leon DD, Hadjiliadis D, Sheikh S, Stefanovski D, Gallop R, D’Alessio DA, Rubenstein RC, Kelly A, Rickels MR. Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis. Diabetes. 2022;71(10):2153–65. https://doi.org/10.2337/db22-0399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Geyer MC, Sullivan T, Tai A, Morton JM, Edwards S, Martin AJ, Perano SJ, Gagliardi L, Rayner CK, Horowitz M, Couper JJ. Exenatide corrects postprandial hyperglycaemia in young people with cystic fibrosis and impaired glucose tolerance: a randomized crossover trial. Diabetes Obes Metab. 2018;21(3):700–4. https://doi.org/10.1111/dom.13544.

    Article  CAS  PubMed  Google Scholar 

  45. Gnanapragasam H, Mustafa N, Bierbrauer M, Andrea Providence T, Dandona P. Semaglutide in cystic fibrosis-related diabetes. J Clin Endocrinol Metabol. 2020;105(7):2341–4. https://doi.org/10.1210/clinem/dgaa167.

    Article  Google Scholar 

  46. Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, Borowski R, Kuhadiya ND, Chaudhuri A, Dandona P. Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22(10):1742–52. https://doi.org/10.1111/dom.14090.

    Article  CAS  PubMed  Google Scholar 

  47. McIntosh CHS, Demuth H-U, Pospisilik JA, Pederson R. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul Pept. 2005;128(2):159–65. https://doi.org/10.1016/j.regpep.2004.06.001.

    Article  CAS  PubMed  Google Scholar 

  48. Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557–67. https://doi.org/10.1111/ijcp.12361.

    Article  CAS  PubMed  Google Scholar 

  49. Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2019;22(4):699–704. https://doi.org/10.1111/dom.13924.

    Article  CAS  PubMed  Google Scholar 

  50. Brennan A, Elisaus P, Bianco B, Cottam S, Pickles J, Tofeec K, Beynon J. P301 metformin tolerability in patients with cystic fibrosis. J Cyst Fibros. 2019;18:S142. https://doi.org/10.1016/s1569-1993(19)30594-6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA

    Ryan Richstein & Trisha Menon

  2. Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA

    Janice Wang

Authors
  1. Ryan Richstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Trisha Menon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Janice Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryan Richstein .

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Long Island Jewish Medical Center, Northwell Health, New Hyde Park, NY, USA

    Rifka C. Schulman-Rosenbaum

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Richstein, R., Menon, T., Wang, J. (2023). Cystic Fibrosis-related Diabetes. In: Schulman-Rosenbaum, R.C. (eds) Diabetes Management in Hospitalized Patients. Contemporary Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-031-44648-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-44648-1_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-44647-4

  • Online ISBN: 978-3-031-44648-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation